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Currently, the optimal anticoagulant therapy to use during pregnancy in patients with mechanical prosthetic valves 
(MPVs) remains controversial, with the published 
international guidelines lacking a clear-cut consensus 
on the issue.1‒4 This is due to the fact that presently 
there is no anticoagulant available which results 
in both an excellent maternal outcome, defined by 
fewer thromboembolic events (TEs), and minimal 
fetal damage, which is defined by the prevention of 
fetal loss or embryopathy. The case study that follows 
focuses on a pregnant patient with prosthetic valve 
thrombosis who was administered a fixed dose of low-
molecular-weight heparin (LMWH) throughout her 
first pregnancy. The leading international guidelines 
are then evaluated and a simplified approach to 
managing this type of patient is proposed.
Case Study
A 28-year-old Omani pregnant woman was admitted 
to a regional hospital in Oman in August 2009 for 
monitoring. She had received a St. Jude Medical™ 
standard bileaflet MPV (St. Jude Medical, Inc., Saint 
Paul, Minnesota, USA) for mitral regurgitation in 
the UK 15 years previously. The patient had been on 
regular warfarin (6 mg per day) since receiving the 
implant with good international normalised ratio (INR) 
control. When her pregnancy had become apparent in 
January 2009, the warfarin was stopped and she was 
begun on LMWH instead. She was prescribed dalteparin 
which was administered subcutaneously once 
daily at a dosage of 10,000 IU. She continued taking 
LMWH throughout her pregnancy without being 
monitored for her anti-factor Xa levels as such 
monitoring was not available at the regional hospital. 
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abstract: Choosing the best anticoagulant therapy for a pregnant patient with a mechanical prosthetic valve is 
controversial and the published international guidelines contain no clear-cut consensus on the best approach. This 
is due to the fact that there is presently no anticoagulant which can reliably decrease thromboembolic events while 
avoiding damage to the fetus. Current treatments include either continuing oral warfarin or substituting warfarin 
for subcutaneous unfractionated heparin or low-molecular-weight heparin (LMWH) in the first trimester 
(6–12 weeks) or at any point throughout the pregnancy. However, LMWH, while widely-prescribed, requires close 
monitoring of the blood anti-factor Xa levels. Unfortunately, facilities for such monitoring are not universally 
available, such as within hospitals in developing countries. This review evaluates the leading international 
guidelines concerning anticoagulant therapy in pregnant patients with mechanical prosthetic valves as well as 
proposing a simplified guideline which may be more relevant to hospitals in this region.
Keywords: Heart Valve Prosthesis; Pregnancy; Warfarin; Low-Molecular-Weight Heparin; Thrombosis.
امللخ�ش: ل يزال هختيار العالج الأمثل ملنع تخرث الدم على ال�شمامات ال�شناعية اأثناء احلمل حمل نقا�ش كما اأن الإر�شادات العالجية 
الدم ويف  الذي مينع تخرث  العالج  الرئي�ش لذلك هو عدم توفر  ال�شبب  اأن  الأمثل. واحلقيقة  ل حتوي توجيهات وا�شحة بالن�شبة للعالج 
ذات الوقت ل ي�رض باجلنني. يف الوقت احلايل هناك طريقان للعالج: الأول يتمثل يف ا�شتمرار تعاطي دواء الوارفارين والآخر ا�شتبدال 
الوارفارين بحيث يتعاطى املري�شا لهيبارين غري املجزأ املعطى حتت اجللد اأو الهيبارين ذا الوزن اجلزيئي املنخف�ش من 12-6 اأ�شبوع 
من احلمل اأو خالل اأي فرتة اأثناء احلمل.ورغم اأن اأنواع الهيبارين ذات الوزن اجلزيئي املنخف�ش ت�شتعمل وبكرثة يف هذه احلالت اإل اأن 
متابعة العالج حتتاج اإىل فح�ش م�شتويات م�شاد العامل )Xa( يف الدم، ولالأ�شف فإن هذا الفح�ش غري متوفر يف معظم م�شت�شفيات 
البالد النامية. اإن الغر�ش من هذا البحث يتمثل يف مراجعة الإر�شادات والتوجيهات الطبية العاملية التي ن�رضت بخ�شو�ش عالج تخرث 
الدم يف الن�شاء احلوامل وكذلك حماولة تقدمي طريقة مب�شطة للعالج الأمثل ملثل هذه احلالت يف هذه املنطقة.
مفتاح الكلمات: �شمامات القلب ال�شناعية؛ احلمل؛ الوارفارين؛ الهيبارين ذا الوزن اجلزيئي املنخف�ش؛ تخرث الدم.
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At 36 weeks, the patient underwent an emergency 
Caesarean section due to fetal distress, with a 
resultant live birth. Post-operatively, she developed 
acute pulmonary oedema which was managed with 
diuretics. The patient was then moved to the Royal 
Hospital, a tertiary hospital in Muscat, Oman, for 
further management. Her INR was 1.0 and her 
activated partial thromboplastin time (aPTT) was 30.1 
seconds (range: 27.2–39.1 seconds). 
A transthoracic echocardiogram of the MPV 
showed a peak pressure gradient of 43 mmHg, a 
mean gradient of 25 mmHg (which had risen from 
a previously reported gradient of 16 mmHg at her 
regional hospital) and a calculated mitral valve area 
of 0.9 cm2. There was a loss of movement in one of 
the leaflets of the MPV. There was mild tricuspid 
regurgitation with a pulmonary artery systolic pressure 
of 85 mmHg and a left ventricular ejection fraction of 
60%. Transoesophageal echocardiography confirmed 
the presence of one immobile leaflet and detected a 
large soft immobile thrombus (1 cm2) towards the atrial 
side [Figures 1A & B]. In view of the patient’s recent 
surgery, thrombolysis was contraindicated. After a 
week-long continuous infusion of unfractionated 
heparin (UFH) with aPTT monitoring, the mean 
gradient on a repeat transthoracic echocardiogram 
was 16 mmHg. There were no embolic complications 
or bleeding. However, fluoroscopy showed that one of 
the leaflets was stuck in the closed position [Figures 
2A & B]. The patient underwent a successful redo 
mitral valve replacement surgery using a size 27 St. 
Jude Medical™ MPV (St. Jude Medical, Inc.). At a one-
year follow-up, the patient was doing well and had a 
normally functioning MPV.  
International Guidelines
Current management strategies for pregnant women 
Figure 1 A & B: Transoesophageal echocardiograms showing (A) a large, soft clot over the mechanical prosthetic bileaflet 
mitral valve on the atrial side (arrowheads) and (B) a thrombus with the immobile leaflet of a mechanical prosthetic 
bileaflet mitral valve in a closed position (arrowheads). The other leaflet can be seen to be opening well. 
LA = left atrium.
Figure 2 A & B: Fluoroscopy showing (A) the immobile leaflet of the mechanical prosthetic bileaflet mitral valve stuck in 
the closed position, while (B) the opposite leaflet opens well.
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ACC/AHA guidelines, the 2011 European Society of 
Cardiology (ESC) guidelines for managing patients 
with valvular heart disease is very similar.3 These 
guidelines recommend that patients requiring less 
than 5 mg of warfarin per day should continue warfarin 
until 36 weeks of gestation (with an embryopathy risk 
of <3%), while those requiring more than 5 mg should 
switch to dose-adjusted IV UFH or LMWH between 
6–12 gestational weeks.3 In addition, they specifically 
recommend that pregnant patients using LMWH 
should have their anti-factor Xa levels monitored on 
a weekly basis; peak anti-factor Xa levels should not 
exceed 0.8–1.2 U/mL approximately 4–6 hours after 
the dose was administered.3
american college of chest 
physicians 
The American College of Chest Physicians (ACCP) 
2012 guidelines recommend the continuation of 
warfarin throughout pregnancy in high-risk patients, 
including patients with an older generation prosthesis, 
a mitral prosthesis or a history of TE, atrial fibrillation 
or left ventricular dysfunction.4 In low-risk patients, 
the dosage should include subcutaneous UFH adjusted 
to attain mid-interval aPTTs of at least twice that of 
the control or anti-factor Xa levels of 0.35–0.70 U/
mL.4 Alternatively, LMWH may be given after 6–12 
gestational weeks or throughout the entire pregnancy. 
The starting dose should be 100 U/kg of dalterparin 
and 1 mg/kg of enoxaparin. The patient should receive 
12 hourly doses subcutaneously to achieve the correct 
peak anti-factor Xa levels four hours post-injection 
and these levels should be checked every week. 
With LMWH, the guidelines suggest that physicians 
should consider additionally prescribing low-dose 
aspirin in high-risk women with MPVs.4 In women 
with a bileaflet aortic valve prosthesis who have been 
prescribed warfarin, the INR target can be 2–3 instead 
of 2.5–3.5.4 
All of the above guidelines agree that LMWH 
should be given twice daily and that it is harmful to 
administer LMWH without regularly monitoring the 
patient’s anti-factor Xa levels.1–4
guidelines for patients after 36 
gestational weeks 
With regard to patient management after 36 
gestational weeks, there is a vast disparity among the 
ACC/AHA, ESC and ACP guidelines. The ACC/AHA 
guidelines suggest stopping warfarin at 36 weeks and 
starting continuous IV UFH with aPTT monitoring, 
which should be continued until approximately 2–3 
weeks before the planned delivery.2 Additionally, they 
recommend that UFH be discontinued 4–6 hours 
(up until 36–38 gestational weeks) with MPVs are 
varied. They include continuous oral warfarin; 
changing from warfarin to subcutaneous UFH or 
LMWH in the first trimester and then back to warfarin; 
continuous subcutaneous UFH, or continuous 
LMWH throughout the duration of the pregnancy.1‒4 
In the absence of controlled clinical trials, most, if not 
all, of these recommendations are based on limited 
observational data. 
american college of 
cardiology/american heart 
association
In their 2008 and 2014 guidelines for the selection of 
an anticoagulation regimen in pregnant patients with 
MPVs, the American College of Cardiology (ACC) 
and American Heart Association (AHA) suggest 
a detailed discussion with the patient regarding 
all of their anticoagulation therapeutic options 
during pregnancy.1,2 Specifically, warfarin is strongly 
recommended in pregnant patients with a MPV to 
achieve a therapeutic INR in the second and third 
trimesters. However, recommendations regarding the 
subcutaneous use of LMWH and UFH throughout 
pregnancy, as well as the subcutaneous use of UFH 
in the first trimester, have been removed completely 
from these guidelines.
According to the 2014 ACC/AHA guidelines, 
the main risk period for complications is within 
the first trimester.1,2 The continuation of warfarin 
during the first trimester is permissible if the dose 
of warfarin does not exceed 5 mg per day. For those 
who require stronger doses of warfarin in the first 
trimester or among those whose preferred treatment 
option is LMWH, the LMWH should be administered 
twice daily and the dose should be adjusted to attain 
peak anti-factor Xa levels of 0.8–1.2 U/mL 
approximately 4–6 hours after the injection. 
Alternatively, to achieve a therapeutic anticoagulation, 
dose-adjusted continuous intravenous (IV) UFH (with 
an aPTT at least twice that of the control) during the 
first trimester is permissible if the dose of warfarin is 
greater than 5 mg per day. In addition, the guidelines 
recommend adding low-dose aspirin (75–100 mg per 
day) in the second and third trimesters. If warfarin 
is the preferred method of treatment throughout 
the pregnancy, the dose should be adjusted to attain 
a target INR of 3.0 (range: 2.5–3.5).1 However, the 
use of IV UFH in the first trimester is difficult from 
a practical standpoint, as a three-month hospital 
admission is required.
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before the planned delivery and restarted 4–6 hours 
after delivery. In the absence of significant bleeding, 
oral warfarin should then be initiated 24 hours after 
the birth.2
ESC guidelines suggest stopping warfarin at 36 
weeks and starting dose-adjusted IV UFH or LMWH.3 
This treatment should continue until 36 hours before 
delivery, when LMWH should be replaced by IV UFH.3 
ACCP guidelines suggest continuing warfarin until 
the patient is close to term (although the word term 
is not specified, it is generally accepted to signify 48 
hours before delivery). At this point, warfarin should 
be replaced by IV UFH or LMWH.4 If labour begins 
spontaneously while the patient is still undergoing 
oral anticoagulation therapy, a Caesarean section 
is indicated due to the baby’s increased risk of 
intracranial bleeding in the case of a vaginal delivery 
or due to other obstetric-related causes.
Clinical Trials
In a retrospective systematic review, Chan et al. 
reported that the use of warfarin in women between 
6–12 gestational weeks resulted in fewer maternal 
TE episodes (3.9%) at the cost of increased fetal loss 
and fetal anomalies (12% and 6.4%, respectively).5 As 
warfarin crosses the placenta, it is associated with 
a high incidence of fetal loss and an increased risk 
of embryopathy which mainly presents as skeletal 
abnormalities (nasal hypoplasia and stippling of the 
vertebrae or bony epiphyses of the extremities).4–7 The 
risk of warfarin-associated embryopathy is markedly 
reduced if warfarin is used after the first trimester, 
even though there are some reports of central nervous 
system structural anomalies such as microcephaly, 
hydrocephalus and eye abnormalities, including 
microphthalmia and optic atrophy.4–7 The overall rate 
of major bleeding in pregnant patients with MPVs 
is reported to be 2.5%; this rate does not change 
according to the type of anticoagulation therapy used.5 
However, the risk of embryopathy is lower among 
patients whose warfarin doses do not exceed 5 mg per 
day.6  
In a prospective cohort study of 250 pregnant 
patients with MPVs, 150 patients continued warfarin 
throughout their pregnancies; there were no 
incidences of valve thrombosis or coumarin-induced 
fetal malformations among this group in comparison 
to those receiving UFH.7 In another study of 196 
pregnancies in 110 women, 142 women continued 
warfarin during their pregnancy, with an increased 
incidence of fetal loss (46% versus 14% for those 
in the UFH group).8 In contrast, the UFH group 
demonstrated a higher rate of valve thrombosis (13% 
versus 2.1%) when used during the first trimester.8 A 
study by Chan et al. found that UFH (dose-adjusted 
so that the aPTT is twice that of the control six hours 
after the injection) appears to demonstrate good 
fetal outcomes, with the treatment not crossing the 
placenta.5 However, this result came at the cost of an 
increased rate of TE complications, with TEs occurring 
in 33% of cases when UFH was used throughout the 
pregnancy and 9% of cases when it was used for the 
first trimester only.5
Therapeutic doses of LMWH, which does not 
cross the placenta, are increasingly being used as 
an alternative option either in the first trimester 
or throughout the entire pregnancy, both with and 
without anti-factor Xa monitoring, as seen in a single-
centre study by Quinn et al.9 However, in a study of 
81 patients, Oran et al. found an overall incidence of 
prosthetic valve thrombosis in 8.6% and an overall TE 
rate of 12.3%.10 Of the 10 patients who suffered a TE, 
nine had received a fixed dose of LMWH; in two of 
these, a low fixed dose was used without anti-factor Xa 
monitoring.10 This was the same therapy option used 
for the 28-year-old woman in the aforementioned case 
study. In the same study, only one patient was reported 
to have had a TE among 51 pregnancies where anti-
factor Xa levels were monitored.10 Thus, a careful 
review of previously reported cases of prosthetic valve 
thrombosis while on LMWH indicates that most of 
these cases were associated with an inadequate dosage, 
a lack of monitoring or sub-therapeutic anti-factor Xa 
levels. 
Another study observed TE complications in seven 
out of 47 pregnancies, of which five were associated 
with the use of enoxaparin therapy.11 The predominant 
causative factors for these complications, which 
were identified in all cases, were poor compliance 
with the therapy requirements and sub-therapeutic 
peak anti-factor Xa levels.11 There is evidence that, 
as LMWH undergoes renal clearance, there is an 
increase in the glomerular filtration rate and plasma 
volume expansion during pregnancy, which leads 
to a higher clearance of LMWH with lower plasma 
concentrations.12,13 In addition, there is increased 
activity of the placental heparinase, which means that 
an increased dose of LMWH is required in order to 
achieve therapeutic anti-factor Xa levels.12,13 Quinn 
et al. found that, in order to maintain adequate anti-
factor Xa levels during pregnancy, the mean LMWH 
dose had to be increased over the initial dose by 54%.9
Fixed-dose regimens or the administration of 
LMWH by weight alone have therefore proven to 
be inadequate; as a result, guidelines advise peak 
anti-factor Xa level monitoring. However, even peak 
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prosthetic valve replacements. The warfarin group 
had a higher incidence of spontaneous abortion than 
the heparin group, although this was not statistically 
significant.22 This study concluded that the role of 
warfarin in warfarin-associated embryopathy had 
been overstated.22 
Is There a Role for 
Prevention?
Of late, the surgical community has advocated 
against giving mechanical prostheses to women 
of a childbearing age.23 In addition, great progress 
has been made in valve-sparing surgeries.24 If a 
prosthesis is really necessary, the ESC guidelines for 
valvular diseases outline the possibility of giving 
bioprostheses to younger patients who choose this 
option and have been informed of the risks (class I).25 
Bioprostheses should also be considered in young 
women contemplating pregnancy (class IIa), with the 
understanding that they may have to undergo another 
operation in the future or a transcatheter valve-in-
valve implantation procedure.25 Moreover, the Ross 
procedure for aortic valve replacement surgery could 
be used in carefully selected patients.24
A Simplif ied Guideline 
Based on the above review of the three major 
guidelines and large meta-analysis, the authors of this 
review recommend a simple approach with regards to 
anticoagulation therapy during pregnancy in patients 
with an MPV. This recommendation is easy for both 
patients and physicians to follow and takes into 
account the fact that anti-factor Xa level monitoring 
may not be available in all centres. 
It is recommended that pregnant women with an 
MPV continue warfarin until 37 gestational weeks or 
one week prior to delivery. This recommendation is 
appropriate for patients who require warfarin at doses 
of either above or below 5 mg per day. However, it is 
important that practitioners discuss the significant 
maternal benefit and the fetal risk of this therapy 
option with their patient and advise them that fetal 
loss is more common than embryopathy. The patients’ 
INR should be measured on a monthly basis in order 
to maintain a target INR of 3.0 (range: 2.5–3.5). 
After 37 weeks’ gestation, or one week prior to a 
planned delivery, warfarin should be stopped and INR 
levels should be monitored on a daily outpatient basis. 
Once the patient’s INR decreases to <2.5, a therapeutic 
dose of weight-based LMWH should be administered 
subcutaneously twice daily to attain peak anti-
anti-factor Xa levels may not reflect the adequacy of 
anticoagulation for periods between 12–24 hours.14–17 
Fan et al. studied the relationship between 177 
paired peak and trough anti-factor Xa levels during 
pregnancy.18 They found that that pregnant patients 
who received adjusted-dose enoxaparin (given every 
12 hours with peak levels of 0.7–1.2 IU/mL) were 
associated with sub-therapeutic trough levels, with a 
pre-dose level of <0.6 IU/mL in >50% of the cases.18 
Thus, the previously mentioned guidelines ignore 
manufacturer recommendations to monitor both peak 
and trough levels.16,19 
A Large Meta-Analysis
In a recent large meta-analysis of studies evaluating 
anticoagulation in pregnant patients with mechanical 
heart valves, Malik et al. identified eight out of 281 
articles that gave the best evidence towards answering 
the research question, Is there a suitable method of 
anticoagulation in pregnant patients with mechanical 
prosthetic heart valves?20 Malik et al. observed that 
while it is traditionally believed that oral anti-
coagulation in pregnancy can lead to warfarin 
embryopathy, only one study reported a higher 
incidence of fetal anomalies with warfarin use 
(6.4%), while two others reported no instances 
of embryopathy at all.20 Fetal mortality with oral 
anticoagulation therapies ranged from 1.52–76% and 
all of the studies demonstrated excellent maternal 
outcomes with warfarin use, with TE events ranging 
from 0–10% in comparison to 4–48% when heparin 
was used. Thus, it was concluded that warfarin is a 
more durable anticoagulant with improved maternal 
outcomes, despite the increased fetal risk.20
This finding was confirmed in a study of 32 
pregnancies by Basude et al.21 While the rate of fetal 
loss in the warfarin group was high, all women in 
the LMWH group, and half of those who received 
LMWH in the first trimester and then subsequently 
received warfarin, had serious adverse maternal 
events, including valve thrombosis, maternal death 
and postpartum haemorrhage.21 In an Omani study, 
Al-Lawati et al. reported on 63 pregnancies in 21 
women with mechanical heart valves.22 The women 
received either warfarin throughout the entire 
duration of their pregnancy or subcutaneous heparin 
in their first trimester and oral warfarin for the rest 
of their pregnancy.22 No cases of warfarin-associated 
embryopathy were observed and there were no 
instances of maternal death. Life-threatening valve 
thrombosis occurred in two patients, both of whom 
were in the heparin group and needed emergency 
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factor Xa levels of 0.8–1.2 U/mL at 4–6 hours post-
administration. 
At 36 hours before delivery, the patient should be 
admitted to the hospital. LMWH should be continued, 
with the last dose given 12 hours prior to the delivery 
and restarted six hours after the delivery. Oral warfarin 
should be given after 24 hours, in the absence of any 
significant bleeding. 
In centres where anti-factor Xa level monitoring 
is not available, the patient should be admitted to the 
hospital at 37 gestational weeks or one week prior 
to a planned delivery. At this point, warfarin should 
be stopped and the INR should be measured daily. 
Once INR levels fall to <2.5, IV UFH therapy should 
commence, with six-hourly aPTT monitoring in order 
to keep the aPTT twice that of the control. The UFH 
should be discontinued 4–6 hours before delivery 
and restarted 4–6 hours after delivery. Oral warfarin 
should be administered after 24 hours, in the absence 
of any significant bleeding. 
For patients who were receiving a very high pre-
pregnancy dose of warfarin (>10 mg), practitioners 
should consider LMWH treatment in the first 
trimester with anti-factor Xa level monitoring. If 
required, treating physicians should seek facilities to 
monitor anti-factor Xa levels in such special cases.
In all cases, the management and treatment of 
patients should follow a ‘team’ approach, with input 
from cardiologists, haematologists and obstetricians. 
Additionally, these recommendations have been 
suggested for the management of patients in 
developing countries and regional hospitals without 
regular access to anti-factor Xa level monitoring and 
in whom alternative treatments are difficult to apply.
Conclusion
In summary, the best anticoagulant treatment for 
pregnant women with an MPV is dependent on the 
availability of anti-factor Xa level monitoring facilities, 
the patient’s pre-pregnancy dose of warfarin and 
the type of anticoagulant preferred by the patient in 
relation to the maternal and fetal risks. Regardless of 
the facilities available or previous treatment received, 
a pregnant woman who requires anticoagulants due to 
the presence of an MPV should be closely monitored 
by a team of healthcare practitioners, including 
cardiology, haematology and obstetric specialists. The 
simplified guidelines proposed in this review article 
are primarily for patients in hospitals that are not able 
to measure anti-factor Xa levels regularly or those who 
are unable to consider alternative treatments.
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